Buscar
Denali Therapeutics Inc
DNLIAñadir a la lista de seguimiento
24.040USD
+0.470+1.99%
Cierre 07-28 16:00（ET）Cotizaciones retrasadas 15 min
3.81BCap. mercado
PérdidaP/E TTM
Más Datos de Denali Therapeutics Inc Compañía
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.
Información de Denali Therapeutics Inc
Símbolo de cotizaciónDNLI
Nombre de la empresaDenali Therapeutics Inc
Fecha de salida a bolsaDec 08, 2017
Director ejecutivoWatts (Ryan J)
Número de empleados422
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 08
Dirección161 Oyster Point Blvd.
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Teléfono16508668547
Sitio Webhttps://www.denalitherapeutics.com
Símbolo de cotizaciónDNLI
Fecha de salida a bolsaDec 08, 2017
Director ejecutivoWatts (Ryan J)
Ejecutivos de Denali Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.45M
-2.04%
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
806.58K
+0.12%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
358.94K
+1.79%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
79.13K
+8.10%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
33.94K
+18.88%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
32.48K
+19.73%
Dr. Marc Tessier-Lavignec, Ph.D.
Dr. Marc Tessier-Lavignec, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven E. (Steve) Krognes
Mr. Steven E. (Steve) Krognes
Director
Director
--
--
Ms. Nancy A. Thornberry
Ms. Nancy A. Thornberry
Independent Director
Independent Director
--
--
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.45M
-2.04%
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
806.58K
+0.12%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
358.94K
+1.79%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
79.13K
+8.10%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
33.94K
+18.88%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
32.48K
+19.73%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Denali Therapeutics Inc?
Los cinco principales accionistas de Denali Therapeutics Inc son: Dr. Ryan J. Watts, Ph.D.
¿Cuántas instituciones poseen acciones de Denali Therapeutics Inc (DNLI)?
A fecha de 2026Q1, 555 instituciones poseen acciones de Denali Therapeutics Inc, con un valor de mercado combinado de aproximadamente 158.73M, lo que representa el 100.01% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 922456.00.